OBSIDENTS

SANOFI



OLIVIER BRANDICOURT "With the performance we delivered in the third-quarter, Sanofi has returned to growth. We have delivered on our promise to shareholders, while bringing important new medicines and treatments to patients around the world."



€9,392M | +6.3% (+3.7%)

€1.84 | +11.2% (+8.2%)

NET SALES*

BUSINESS EPS*

*Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis

Sales by global business unit

€3,160 м

General Medicines & Emerging Markets

€**2,069** M

Sanofi Pasteur (Vaccines)

€1,904 м

X

Sanofi Genzyme (Specialty Care)

€**1,146** м

Diabetes & Cardiovascular

€1,113 м

Consumer Healthcare



**Rest of the World: Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico









projects in development, including new molecular entities & additional indications

projects in Phase 3 or submitted for approval

For further information on Q3 2018 results and definitions of financial indicators, please refer to the press release issued on October 31, 2018, at

HTTPS://WWW.SANOFI.COM/INVESTORS/

